IMPLANET, a company specializing in spinal implants, announces the first placements of its JAZZ system in China, marking a major turning point in its international expansion strategy.
In collaboration with Sanyou Medical, IMPLANET has completed the registration of its JAZZ range in the Chinese market, the largest in terms of volume potential. Following the approval from the CFDA in July 2025, the first implants were delivered in September and showcased at the Chinese Orthopedic Association's congress in November. The initial surgeries were performed in Hainan by Dr. Huanxiang Chen after intensive training in France.
Intensive Skill Transfer and Training
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The success of this launch relies on an intensive skill transfer, with a two-month training program for Dr. Chen in France. This program was supervised by renowned experts, ensuring the use of the JAZZ® system according to international standards of quality and safety. IMPLANET and Sanyou Medical aim for a structured and gradual deployment, with further surgeries planned in Shanghai and Beijing.
Strategic Milestone Acknowledged by CEO
Ludovic Lastennet, CEO of IMPLANET, praises this advancement as a crucial strategic step. The Chinese approval and the successful initial operations confirm the clinical value of the system in a key market. The upcoming installations in Shanghai and Beijing demonstrate IMPLANET's ambition for a sustainable deployment in China.
Related
SectorÉquipements et Services Médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Guidance from the release
Ce premier trimestre 2026 marque une nouvelle étape dans la dynamique de croissance d’IMPLANET.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
